Samsung Biologics plans to separate CDMO, biosimilar biz
Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar development business to streamline its operations and focus on its core contract development and manufacturing organisation (CDMO) services.
According to a regulatory filing, the company will establish a new entity, Samsung Epis Holdings, which will later incorporate Samsung Bioepis Co., a biosimilar drug developer, as a wholly owned subsidiary, reports Yonhap news agency.
The spinoff process will proceed with the submission of a securities report on July 29, followed by a shareholders meeting on Sept. 16 for final approval.
Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to biosimilars.
CDMO refers to a company that handles not only the outsourced manufacturing of drug substances but also all of the innovation and development work that occurs prior to production.
In particular, the company acknowledged that some customers have raised concerns over the possibility that proprietary technologies for original drugs might be shared with Samsung Bioepis, which operates in the biosimilar space.
"As Samsung Bioepis has been expanding its biosimilar business, the concerns of Samsung Biologics' customers have gradually increased, which has had some impact on the competitiveness of our orders," said Ryu Seung-ho, chief financial officer at Samsung Biologics, during an online briefing.
"After the separation, we expect our customers' concerns about conflicts of interest will be better addressed."
Samsung Biologics originally established Samsung Bioepis as a joint venture with U.S. pharmaceutical company Biogen Inc. in 2012. It acquired Biogen's stake for US$2.3 billion in 2022, making Bioepis a wholly-owned subsidiary.
Ryu also emphasized that the spinoff is not part of any broader corporate governance restructuring within Samsung Group.
In a separate statement, Samsung Bioepis said the spinoff will not impact its day-to-day operations.
"Samsung Bioepis' ongoing business operations, including research and development, manufacturing, supply distribution and commercialization of biologic medicines, will not be affected by the spinoff," the company said.
"We will continue to focus on our core business, and we remain committed to ensuring the continued development, manufacturing and distribution of high-quality biosimilar medicines to patients around the world without any disruption."
By separating the two businesses, Samsung Biologics said it aims to reinforce the independence of both entities, allowing each to sharpen its strategic focus. The company said this will enhance competitiveness, operational efficiency and long-term value for shareholders.
Samsung Biologics is one of the world's leading CDMO firms, reporting 4.54 trillion won ($3.3 billion) in sales and 1 trillion won in net profit in 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
Skoda, Mercedes, Kia, Hyundai keen to manufacture EVs in India: Kumaraswamy
Union Minister H D Kumaraswamy announced that Mercedes Benz, Skoda-Volkswagen, Hyundai, and Kia are considering manufacturing electric vehicles in India, with the application window for the SPMEPCI opening soon. The scheme aims to boost domestic EV production and reduce emissions, offering incentives for manufacturers who invest and produce EVs locally. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Europe's Mercedes Benz, and Skoda-Volkswagen (VW), and South Korea's Hyundai and Kia, have shown interest to manufacture electric vehicles (EVs) in India, Union Heavy Industries Minister H D Kumaraswamy said journalists, he said application window for the Scheme to Promote Manufacturing of Electric Passenger Cars in India (SPMEPCI) will soon open, after which formal requests will be to queries on Tesla's India plans, Kumaraswamy said the US-headquartered EV maker has not shown any interest to make in India.'Tesla only wants to open showrooms and sell imported cars,' he the SPMEPCI guidelines, the minister said this aligns with India's emission reduction goals.'The benefit is available only if the company agrees to invest and manufacture EVs on India,' he said the beneficiaries will need to start domestic production between three years.'This will enhance India's status as a global EV manufacturing hub…applications window for seeking sops to open shortly,' he officials aware of the developments said Skoda-Volkswagen (VW), and Mercedes Benz may shortly announce investment plans. The car makers are expected to seek sops under scheme is aimed at encouraging fresh investments from global manufacturers in EV passenger cars segment. To encourage the global manufacturers to invest under the scheme, approved applicants will be allowed to import Completely Built-in Units (CBUs) of electric four wheelers with a minimum import value of $ 35,000 at reduced customs duty of 15% for five the scheme guidelines, approved applicants would be required to make minimum investment of Rs. 4,150 crore in line with the provisions of the scheme. The maximum number of cars allowed to be imported at the reduced duty rate shall be capped at 8,000 units per year.
Mint
an hour ago
- Mint
Gold investment demand surges 170% in March 2025 quarter, driven by ETF inflows and Central Bank buying
Gold markets witnessed a historic uptrend in the March quarter of 2025, with investment demand skyrocketing by 170 percent year-on-year, according to the May Alpha Strategist Report released by Motilal Oswal Private Wealth. The surge was largely propelled by a revival in exchange-traded fund (ETF) inflows amid global economic instability, mounting geopolitical tensions, and the weakening US dollar. Despite only a marginal increase in supply, the value of the gold market soared, reinforcing its safe-haven status. Motilal Oswal Private Wealth highlighted that gold investment demand in the March quarter surged to 552 tonnes, marking a remarkable 170 percent jump compared to the same quarter last year. This spike nearly matched the post-Russia-Ukraine war demand seen in March 2022 quarter. The surge was underpinned by strong ETF inflows globally, with holdings expanding by 226 tonnes in the quarter. European-listed funds added 55 tonnes, bolstered by expectations of further rate cuts from the European Central Bank. Meanwhile, Asian-listed ETFs added 34 tonnes, with a significant portion coming from China due to rising US-China trade tensions. India also posted robust ETF demand, recording an 11 percent increase in holdings. The report from Motilal Oswal Private Wealth also underscored that geopolitical uncertainty, stock market volatility, and ongoing tariff wars played a key role in pushing gold prices to record levels. Domestically, India's spot gold price surged 23 percent year-to-date to ₹ 93,217 per 10 grams. Globally, the total gold supply stood at 1,206 tonnes in Q1 2025, up by 1 percent year-on-year — the highest level for a first quarter since 2016. While supply rose modestly, the value of the gold market climbed an impressive 40 percent YoY, reflecting the sharp price increase. Furthermore, Central bank gold purchases remained resilient in March 2025 quarter, as per Motilal Oswal Private Wealth. Total official sector purchases stood at 244 tonnes — 24 percent above the five-year quarterly average, although slightly lower than the preceding quarter. Emerging market central banks led the buying spree, continuing their reserve diversification strategies and reducing exposure to US dollar assets. The persistent uncertainty across global markets reinforced gold's appeal as a reserve asset. As per the report, the Reserve Bank of India (RBI) added 0.6 tonnes of gold in March 2025, bringing its total holdings to 879.6 tonnes — accounting for 11.7 percent of its total forex reserves. Over the past year, the RBI has increased its gold reserves by 57.5 tonnes. However, recent purchases have moderated, suggesting a more cautious and strategic approach despite gold's growing role in India's monetary reserve portfolio. Amid record prices, it also noted a significant contraction in global jewelry demand, particularly in India. Jewelry consumption in the country fell 25 percent YoY to 71 tonnes in March 2025 quarter, the lowest quarterly volume since Q3 2020. Still, the value of Indian jewelry demand rose 3 percent YoY, owing to higher gold prices. Consumers adapted by purchasing lighter pieces or exchanging old jewelry for new, with 40–45 percent of transactions involving some form of exchange. The popularity of gold-backed loans also continued to rise. While wedding-related purchases remained relatively stable, they failed to offset the decline in discretionary buying. Although high prices weighed heavily on jewelry consumption, especially in India, gold remained a core component of strategic reserves and investment portfolios. With geopolitical tensions, market volatility, and interest rate expectations continuing to influence investor sentiment, gold's status as a resilient hedge appears stronger than ever. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
2 hours ago
- Economic Times
India and China are promising alternatives for investment, says Mirae Asset VC
Mirae Asset suggests India and China as promising investment alternatives amid concerns over US economic dominance and policy shifts. Mirae Asset suggests India and China as investment alternatives. This comes amid concerns about over-reliance on the US economy. Weakening global confidence and rising nationalism are factors. India's digital infrastructure and population growth are attractive. China's policy shifts are also creating opportunities. Foxconn plans a significant investment in its India unit. South Korean exports to the US have declined recently. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India and China emerge as promising alternatives for investments, said Mirae Asset Securities Vice Chairman Heo Sun-ho while speaking at a global asset allocation forum in Seoul on Thursday, reports Korea the return of US President Donald Trump to the Oval Office, crack seems to emerge 'in the US-centered investment landscape'. Speaking at the summit hosted by Mirae Asset, Heo-Sin-ho said the over-dependence on the US as its primary growth engine needs to be re-examined."The recent depreciation of the US dollar reflects weakening global confidence, spurred by growing nationalism and ballooning fiscal deficits," Heo said, urging investors to pivot from a US-centric strategy and realign their portfolios with the shifting global innovation vice chairman mentioned that India is emerging as a vast consumer market, driven by robust digital infrastructure and a rapidly expanding to Heo Sun-ho, "Innovative technology that once fuelled US growth is no longer its exclusive domain."He also cited how Chinese AI Startup, DeepSeek positioning itself as a challenger to OpenAI, alongside Chinese automobile company BYD which in April overtook Tesla in the European electric vehicle market for the first to the director and head of Asia Pacific Research at Mirae Asset Hong Kong, policy shifts in China are also creating a more favourable environment for foreign investors. He also echoed the call for a diversified investment South Korean exports to US were down 8.1 per cent for the month of May, as compared to same month last year, weighed down by the US President Donald Trump's tariff, as it took a toll on automobile supplier Foxconn is set to invest USD 1.5 billion in its India unit, Reuters reported, citing a company filing. (ANI)
